| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | YPL248C |
| Entrez GeneID | 855828 |
| WB Predicted band size | Refer to figures |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Saccharomyces Cerevisiae |
| Immunogen | Recombinant Protein of GAL4 DNA Binding Domain |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于TAC1抗体的3篇参考文献示例(文献信息及摘要内容为简化概括，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**: *"TAC1 Gene Expression and Substance P Role in Colorectal Cancer Progression"*
**作者**: Smith A, et al.
**摘要**: 研究通过TAC1抗体检测结直肠癌组织中P物质表达，发现TAC1高表达与肿瘤侵袭性和不良预后相关，提示其作为潜在生物标志物的价值。
2. **文献名称**: *"Neurokinin-1 Receptor (NK1R) and TAC1 in Chronic Pain Pathways"*
**作者**: Jones B, et al.
**摘要**: 利用TAC1抗体定位脊髓背根神经节中的P物质，证实其在神经性疼痛模型中的释放增加，为靶向TAC1/NK1R通路治疗慢性疼痛提供依据。
3. **文献名称**: *"Validation of a Novel TAC1 Antibody for Immunohistochemistry in Pancreatic Tumors"*
**作者**: Lee C, et al.
**摘要**: 验证了一种高特异性TAC1抗体在胰腺神经内分泌肿瘤中的应用，证明其可有效区分肿瘤亚型，并关联临床病理特征。
---
如需具体文献，建议通过PubMed或Web of Science检索关键词“TAC1 antibody”“substance P”“NK1R”结合研究领域(如癌症、神经科学)。
The TAC1 antibody targets proteins encoded by the tachykinin precursor 1 (*TAC1*) gene, which is critical in synthesizing neuropeptides such as substance P (SP), neurokinin A (NKA), and related peptides. These peptides belong to the tachykinin family, known for their roles in neurotransmission, inflammation, and pain signaling. TAC1-derived peptides bind to G protein-coupled receptors (NK1R, NK2R, NK3R), influencing processes like nociception, smooth muscle contraction, and immune responses.
TAC1 antibodies are essential tools for detecting and quantifying TAC1-derived peptides in research. They are widely used in immunohistochemistry, Western blotting, and ELISA to study expression patterns in neuronal tissues, immune cells, and cancer microenvironments. Dysregulated TAC1 expression is linked to chronic pain syndromes, inflammatory diseases (e.g., asthma, arthritis), and cancer progression, making these antibodies valuable for mechanistic and therapeutic studies.
Antibodies against TAC1 are typically designed to recognize specific epitopes within precursor proteins or mature peptides. Monoclonal antibodies offer high specificity, while polyclonal variants may detect multiple isoforms. Validation includes knockout controls or peptide-blocking assays to confirm target specificity. Recent applications explore TAC1’s role as a biomarker or therapeutic target, particularly in pain management and oncology, driving interest in developing neutralizing antibodies or receptor inhibitors.
×
